Trial Profile
A study evaluating safety and efficacy of Grazoprevir-Elbasvir based hepatitis c virus therapy in patients with chronic kidney disease who are on renal replacement therapy in a community based setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jul 2017
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 08 Jul 2017 New trial record